Biogen Idec Inc (BIIB) 298.25 $BIIB
You Can't Keep Volatility Down Forever
at The Street - Wed Aug 26, 1:00PM CDT
We saw this coming, but there's more to the recent turmoil than China.
BIIB: 298.25 (+16.51), HACK: 27.14 (+0.93), GILD: 106.96 (+4.40), BHP: 34.08 (+1.16), LH: 117.80 (+3.04), AMGN: 153.98 (+8.79)
Biogen Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors
Business Wire - Wed Aug 26, 11:34AM CDT
Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announce that a federal class action lawsuit has been filed in the United States District Court for the District of Massachusetts against Biogen Inc. ("Biogen"
(NasdaqGS: BIIB) and several officers and directors for acts taken during the period of January 29, 2015 to July 23, 2015 (the "Class Period" .
BIIB: 298.25 (+16.51)
Biotech Stock Roundup: Acorda Gains on Patent Issues, Vital Crushed by Liver Data
Arpita Dutt - Zacks Investment Research - Wed Aug 26, 7:55AM CDT
It was a mixed week for the biotech sector with companies like Acorda (ACOR) and BioMarin (BMRN) providing positive updates while others saw their share prices crashing on disappointing data.
BIIB: 298.25 (+16.51), BMRN: 128.10 (+6.96), VTL: 3.31 (-0.11), MCUR: 3.44 (-0.23), AMGN: 153.98 (+8.79), ACOR: 31.96 (+0.59), ALKS: 60.07 (+2.54)
Acorda (ACOR) Gets Favorable Outcome in Ampyra IPR Issue
Zacks Equity Research - Zacks Investment Research - Tue Aug 25, 3:40PM CDT
Acorda (ACOR) received encouraging news with the patent review board refusing to review two patents related to Ampyra.
AGN: 305.98 (+15.35), BIIB: 298.25 (+16.51), TEVA: 64.82 (+0.61), ACOR: 31.96 (+0.59)
Biogen Idec (BIIB) Approaches New Upside Target of $309.65
Comtex SmarTrend(R) - Tue Aug 25, 10:21AM CDT
Biogen Idec (NASDAQ:BIIB) has opened bullishly above the pivot of $279.50 today and has reached the first level of resistance at $294.00. Investors may be interested in a cross of the next upside pivot targets of $309.65 and $339.80.
BIIB: 298.25 (+16.51)
Acorda Stock Jumps After Bass Patent Petitions Nixed
at Investor's Business Daily - Tue Aug 25, 10:09AM CDT
Biotech stock Acorda Therapeutics (ACOR) soared 18% in early trading in the stock market today, a day after a court dismissed a patent challenge in a move that could have wider implications in the drug space. Late Monday, Acorda announced that the...
BIIB: 298.25 (+16.51), SHPG: 223.81 (+4.35), ABBV: 63.14 (+2.43), ACOR: 31.96 (+0.59)
Biogen (BIIB) Crumbles: Stock Falls by 5.9%
Zacks Equity Research - Zacks Investment Research - Tue Aug 25, 7:51AM CDT
The slump shouldn't be too much of a surprise to investors, as Biogen (BIIB) has seen 11 negative revisions in the past few weeks and its current year earnings consensus has moved lower
BIIB: 298.25 (+16.51), MASI: 40.85 (+1.31)
After Yesterday's Decline of 5.85%, Biogen Idec Offers Investors Better Value
Comtex SmarTrend(R) - Mon Aug 24, 4:54PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $265.00 to a high of $295.15. Yesterday, the shares fell 5.8%, which took the trading range below the 3-day low of $295.46 on volume of 5.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 298.25 (+16.51)
Watch for Biogen Idec to Potentially Rebound After Falling 5.85% Yesterday
Comtex SmarTrend(R) - Mon Aug 24, 4:54PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $265.00 to a high of $295.15. Yesterday, the shares fell 5.8%, which took the trading range below the 3-day low of $295.46 on volume of 5.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 298.25 (+16.51)
Bull Or Bear? Biotech's Post-Earnings Buys and Sells
Todd Campbell and Kristine Harjes, The Motley Fool - Motley Fool - Sun Aug 23, 1:37PM CDT
With earnings season behind us, many investors are wondering which stocks should be queued for a buy in the healthcare market. On this Industry Focus episode, Motley Fool's Kristine Harjes and contributor Todd Campbell discuss second-quarter...
BIIB: 298.25 (+16.51), MNKD: 3.65 (+0.34), ARNA: 2.72 (+0.04), REGN: 535.47 (+36.45)
4 Reasons To Keep An Eye On Top Biotech Celgene
at Investor's Business Daily - Fri Aug 21, 5:06PM CDT
Celgene has pulled back as the market has come under increased selling pressure, but the long-term prospects for the biotech leader remain healthy. Celgene (CELG) develops cancer and immune-inflammatory-related disease therapies, including multiple...
BIIB: 298.25 (+16.51), RCPT: 231.99 (+0.04), AMGN: 153.98 (+8.79), JUNO: 36.50 (+0.69), REGN: 535.47 (+36.45), CELG: 119.23 (+6.53)
Intelligence on: Conjugation Platform Technologies 2015 - Detailed Insights on Future Opportunities
M2 - Thu Aug 20, 3:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nszlzs/intelligence_on) has announced the addition of the "Intelligence on: Conjugation Platform Technologies" report to their offering. The unprecedented success of antibody drug conjugates have lead to a rapid increase in the number of clinical stage candidates. The majority of these first generation ADCs rely on the well validated platforms developed by Seattle Genetics and ImmunoGen. For the industry to continue its rapid development new technologies are essential to increase diversity of approaches, improve the safety and efficacy of the drugs, and target new indications and exploit novel mechanisms of action. 'Intelligence on: Conjugation Platform Technologies' is a scientific report, produced for researchers to review the different technology approaches developed to date and the levels of commercial and scientific validation that has been done on specific platforms. This report focuses on reviewing the available linker and payload technologies suitable for antibody-drug conjugates. Discover what opportunities there are within the global landscape, learn what new conjugation approaches are emerging and read expert perspectives on what the future holds for the field. Providing sought after intelligence on the variety of emerging technologies for antibody drug conjugation, detailed insights will be shared on future opportunities, potential applications as well as current commercial and scientific validation. Key Topics Covered: 1. Introduction, scopes and objectives 2. Antibody conjugates and other payloads 3. Linker technologies 4. Payload platforms 5. Improving payload delivery mechanisms 6. IP challenges, deal structures, mergers and acquisitions; future opportunities 7. Interviews with experts in the field Companies Mentioned - ADC Therapeutics - AREVA Med - Abbvie - Abzena - Actinium Pharmaceuticals - Adimab - Affinicon - Agensys - Algeta - Allozyne - Alpha Cancer Technologies - Ambrx - Amgen - Angiochem - Asana Biosciences - Aspyrian Therapeutics - Astellas - AstraZeneca - BMS - Baxter - Bayer - BiOasis Technologies - BioAlta - Biogen Idec - Biotest - Boehringer Ingelheim - Cancer Research UK - Catalent - Celgene - Celldex - Cellerant Therapeutics - Centrose - Centyrex - Covagen For more information visit http://www.researchandmarkets.com/research/ns...ligence_on
BIIB: 298.25 (+16.51), ATNM: 1.93 (unch), AMGN: 153.98 (+8.79), CELGZ: 1.68 (+0.12)
SmarTrend Watching for Potential Pullback in Shares of Biogen Idec After 1.18% Gain
Comtex SmarTrend(R) - Wed Aug 19, 4:06PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $310.50 to a high of $319.35. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $317.66 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 298.25 (+16.51)
Biogen Idec Set to Possibly Pullback After Yesterday's Rally of 1.18%
Comtex SmarTrend(R) - Wed Aug 19, 4:05PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $310.50 to a high of $319.35. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $317.66 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 298.25 (+16.51)
AGTC Announces Strategic Collaboration With Biogen Effective and Biogen Equity Investment Closed
GlobeNewswire - Wed Aug 19, 3:05PM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced that its collaboration with Biogen (Nasdaq:BIIB), first announced on July 2, 2015 is effective, and Biogen's equity investment in AGTC has closed, following the expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the satisfaction of other customary closing conditions.
AGTC: 15.48 (+0.52), BIIB: 298.25 (+16.51)
Biotech Stock Roundup: Kite Addresses Patient Death Concerns, Omeros Soars on Data
Arpita Dutt - Zacks Investment Research - Wed Aug 19, 7:33AM CDT
Kite Pharma (KITE) provided an update on KTE-C19 and remains on track to provide data later this year at ASH.
BIIB: 298.25 (+16.51), KITE: 51.53 (+1.49), AMGN: 153.98 (+8.79), AAVL: 10.51 (+0.43), ABBV: 63.14 (+2.43), OMER: 16.25 (-0.32)
'Mad Money' Lightning Round: I'm Sticking With My Biotech 'Four Horsemen'
at The Street - Wed Aug 19, 5:00AM CDT
Cramer is staying out of Planet Fitness and Chimera Investment but favors Domino's Pizza and General Dynamics.
GD: 144.05 (+5.21), BIIB: 298.25 (+16.51), WLL: 14.70 (-0.02), GILD: 106.96 (+4.40), FRSH: 14.11 (+0.21), CIM: 13.82 (+0.24), SUNE: 9.22 (+0.42), DPZ: 106.30 (+1.28), PLNT: 15.90 (+0.63), REGN: 535.47 (+36.45), AFFX: 9.24 (+0.41), CELG: 119.23 (+6.53)
Jim Cramer's 'Mad Money' Recap: Housing Alone Can't Build a Rally
at The Street - Tue Aug 18, 6:54PM CDT
Too many stocks are levered to overseas issues, especially China, Cramer warns.
BIIB: 298.25 (+16.51), GD: 144.05 (+5.21), WLL: 14.70 (-0.02), HD: 115.93 (+4.96), SWKS: 86.15 (+5.59), CAFD: 14.21 (+0.03), AFFX: 9.24 (+0.41), CELG: 119.23 (+6.53), HAIN: 60.48 (+0.97), FSLR: 46.09 (+1.71), CIM: 13.82 (+0.24), FRSH: 14.11 (+0.21), GILD: 106.96 (+4.40), SUNE: 9.22 (+0.42), DPZ: 106.30 (+1.28), TWTR: 25.03 (+0.65), PLNT: 15.90 (+0.63), ZU: 17.75 (+0.18), REGN: 535.47 (+36.45)
EQUITY ALERT: The Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Biogen Inc. to Recover Investor Losses
Business Wire - Tue Aug 18, 5:35PM CDT
The Rosen Law Firm, a global investor rights firm, announces that a class action lawsuit has been filed on behalf of all purchasers of Biogen Inc. (NASDAQ:BIIB) securities from January 29, 2015 through July 23, 2015, inclusive (the "Class Period" . The lawsuit seeks to recover investors' losses under the federal securities laws.
BIIB: 298.25 (+16.51)
You Can't Keep Volatility Down Forever
at The Street - Wed Aug 26, 1:00PM CDT
We saw this coming, but there's more to the recent turmoil than China.
BIIB: 298.25 (+16.51), HACK: 27.14 (+0.93), GILD: 106.96 (+4.40), BHP: 34.08 (+1.16), LH: 117.80 (+3.04), AMGN: 153.98 (+8.79)
Biogen Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors
Business Wire - Wed Aug 26, 11:34AM CDT
Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announce that a federal class action lawsuit has been filed in the United States District Court for the District of Massachusetts against Biogen Inc. ("Biogen"
(NasdaqGS: BIIB) and several officers and directors for acts taken during the period of January 29, 2015 to July 23, 2015 (the "Class Period" . BIIB: 298.25 (+16.51)
Biotech Stock Roundup: Acorda Gains on Patent Issues, Vital Crushed by Liver Data
Arpita Dutt - Zacks Investment Research - Wed Aug 26, 7:55AM CDT
It was a mixed week for the biotech sector with companies like Acorda (ACOR) and BioMarin (BMRN) providing positive updates while others saw their share prices crashing on disappointing data.
BIIB: 298.25 (+16.51), BMRN: 128.10 (+6.96), VTL: 3.31 (-0.11), MCUR: 3.44 (-0.23), AMGN: 153.98 (+8.79), ACOR: 31.96 (+0.59), ALKS: 60.07 (+2.54)
Acorda (ACOR) Gets Favorable Outcome in Ampyra IPR Issue
Zacks Equity Research - Zacks Investment Research - Tue Aug 25, 3:40PM CDT
Acorda (ACOR) received encouraging news with the patent review board refusing to review two patents related to Ampyra.
AGN: 305.98 (+15.35), BIIB: 298.25 (+16.51), TEVA: 64.82 (+0.61), ACOR: 31.96 (+0.59)
Biogen Idec (BIIB) Approaches New Upside Target of $309.65
Comtex SmarTrend(R) - Tue Aug 25, 10:21AM CDT
Biogen Idec (NASDAQ:BIIB) has opened bullishly above the pivot of $279.50 today and has reached the first level of resistance at $294.00. Investors may be interested in a cross of the next upside pivot targets of $309.65 and $339.80.
BIIB: 298.25 (+16.51)
Acorda Stock Jumps After Bass Patent Petitions Nixed
at Investor's Business Daily - Tue Aug 25, 10:09AM CDT
Biotech stock Acorda Therapeutics (ACOR) soared 18% in early trading in the stock market today, a day after a court dismissed a patent challenge in a move that could have wider implications in the drug space. Late Monday, Acorda announced that the...
BIIB: 298.25 (+16.51), SHPG: 223.81 (+4.35), ABBV: 63.14 (+2.43), ACOR: 31.96 (+0.59)
Biogen (BIIB) Crumbles: Stock Falls by 5.9%
Zacks Equity Research - Zacks Investment Research - Tue Aug 25, 7:51AM CDT
The slump shouldn't be too much of a surprise to investors, as Biogen (BIIB) has seen 11 negative revisions in the past few weeks and its current year earnings consensus has moved lower
BIIB: 298.25 (+16.51), MASI: 40.85 (+1.31)
After Yesterday's Decline of 5.85%, Biogen Idec Offers Investors Better Value
Comtex SmarTrend(R) - Mon Aug 24, 4:54PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $265.00 to a high of $295.15. Yesterday, the shares fell 5.8%, which took the trading range below the 3-day low of $295.46 on volume of 5.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 298.25 (+16.51)
Watch for Biogen Idec to Potentially Rebound After Falling 5.85% Yesterday
Comtex SmarTrend(R) - Mon Aug 24, 4:54PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $265.00 to a high of $295.15. Yesterday, the shares fell 5.8%, which took the trading range below the 3-day low of $295.46 on volume of 5.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 298.25 (+16.51)
Bull Or Bear? Biotech's Post-Earnings Buys and Sells
Todd Campbell and Kristine Harjes, The Motley Fool - Motley Fool - Sun Aug 23, 1:37PM CDT
With earnings season behind us, many investors are wondering which stocks should be queued for a buy in the healthcare market. On this Industry Focus episode, Motley Fool's Kristine Harjes and contributor Todd Campbell discuss second-quarter...
BIIB: 298.25 (+16.51), MNKD: 3.65 (+0.34), ARNA: 2.72 (+0.04), REGN: 535.47 (+36.45)
4 Reasons To Keep An Eye On Top Biotech Celgene
at Investor's Business Daily - Fri Aug 21, 5:06PM CDT
Celgene has pulled back as the market has come under increased selling pressure, but the long-term prospects for the biotech leader remain healthy. Celgene (CELG) develops cancer and immune-inflammatory-related disease therapies, including multiple...
BIIB: 298.25 (+16.51), RCPT: 231.99 (+0.04), AMGN: 153.98 (+8.79), JUNO: 36.50 (+0.69), REGN: 535.47 (+36.45), CELG: 119.23 (+6.53)
Intelligence on: Conjugation Platform Technologies 2015 - Detailed Insights on Future Opportunities
M2 - Thu Aug 20, 3:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nszlzs/intelligence_on) has announced the addition of the "Intelligence on: Conjugation Platform Technologies" report to their offering. The unprecedented success of antibody drug conjugates have lead to a rapid increase in the number of clinical stage candidates. The majority of these first generation ADCs rely on the well validated platforms developed by Seattle Genetics and ImmunoGen. For the industry to continue its rapid development new technologies are essential to increase diversity of approaches, improve the safety and efficacy of the drugs, and target new indications and exploit novel mechanisms of action. 'Intelligence on: Conjugation Platform Technologies' is a scientific report, produced for researchers to review the different technology approaches developed to date and the levels of commercial and scientific validation that has been done on specific platforms. This report focuses on reviewing the available linker and payload technologies suitable for antibody-drug conjugates. Discover what opportunities there are within the global landscape, learn what new conjugation approaches are emerging and read expert perspectives on what the future holds for the field. Providing sought after intelligence on the variety of emerging technologies for antibody drug conjugation, detailed insights will be shared on future opportunities, potential applications as well as current commercial and scientific validation. Key Topics Covered: 1. Introduction, scopes and objectives 2. Antibody conjugates and other payloads 3. Linker technologies 4. Payload platforms 5. Improving payload delivery mechanisms 6. IP challenges, deal structures, mergers and acquisitions; future opportunities 7. Interviews with experts in the field Companies Mentioned - ADC Therapeutics - AREVA Med - Abbvie - Abzena - Actinium Pharmaceuticals - Adimab - Affinicon - Agensys - Algeta - Allozyne - Alpha Cancer Technologies - Ambrx - Amgen - Angiochem - Asana Biosciences - Aspyrian Therapeutics - Astellas - AstraZeneca - BMS - Baxter - Bayer - BiOasis Technologies - BioAlta - Biogen Idec - Biotest - Boehringer Ingelheim - Cancer Research UK - Catalent - Celgene - Celldex - Cellerant Therapeutics - Centrose - Centyrex - Covagen For more information visit http://www.researchandmarkets.com/research/ns...ligence_on
BIIB: 298.25 (+16.51), ATNM: 1.93 (unch), AMGN: 153.98 (+8.79), CELGZ: 1.68 (+0.12)
SmarTrend Watching for Potential Pullback in Shares of Biogen Idec After 1.18% Gain
Comtex SmarTrend(R) - Wed Aug 19, 4:06PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $310.50 to a high of $319.35. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $317.66 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 298.25 (+16.51)
Biogen Idec Set to Possibly Pullback After Yesterday's Rally of 1.18%
Comtex SmarTrend(R) - Wed Aug 19, 4:05PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $310.50 to a high of $319.35. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $317.66 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 298.25 (+16.51)
AGTC Announces Strategic Collaboration With Biogen Effective and Biogen Equity Investment Closed
GlobeNewswire - Wed Aug 19, 3:05PM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced that its collaboration with Biogen (Nasdaq:BIIB), first announced on July 2, 2015 is effective, and Biogen's equity investment in AGTC has closed, following the expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the satisfaction of other customary closing conditions.
AGTC: 15.48 (+0.52), BIIB: 298.25 (+16.51)
Biotech Stock Roundup: Kite Addresses Patient Death Concerns, Omeros Soars on Data
Arpita Dutt - Zacks Investment Research - Wed Aug 19, 7:33AM CDT
Kite Pharma (KITE) provided an update on KTE-C19 and remains on track to provide data later this year at ASH.
BIIB: 298.25 (+16.51), KITE: 51.53 (+1.49), AMGN: 153.98 (+8.79), AAVL: 10.51 (+0.43), ABBV: 63.14 (+2.43), OMER: 16.25 (-0.32)
'Mad Money' Lightning Round: I'm Sticking With My Biotech 'Four Horsemen'
at The Street - Wed Aug 19, 5:00AM CDT
Cramer is staying out of Planet Fitness and Chimera Investment but favors Domino's Pizza and General Dynamics.
GD: 144.05 (+5.21), BIIB: 298.25 (+16.51), WLL: 14.70 (-0.02), GILD: 106.96 (+4.40), FRSH: 14.11 (+0.21), CIM: 13.82 (+0.24), SUNE: 9.22 (+0.42), DPZ: 106.30 (+1.28), PLNT: 15.90 (+0.63), REGN: 535.47 (+36.45), AFFX: 9.24 (+0.41), CELG: 119.23 (+6.53)
Jim Cramer's 'Mad Money' Recap: Housing Alone Can't Build a Rally
at The Street - Tue Aug 18, 6:54PM CDT
Too many stocks are levered to overseas issues, especially China, Cramer warns.
BIIB: 298.25 (+16.51), GD: 144.05 (+5.21), WLL: 14.70 (-0.02), HD: 115.93 (+4.96), SWKS: 86.15 (+5.59), CAFD: 14.21 (+0.03), AFFX: 9.24 (+0.41), CELG: 119.23 (+6.53), HAIN: 60.48 (+0.97), FSLR: 46.09 (+1.71), CIM: 13.82 (+0.24), FRSH: 14.11 (+0.21), GILD: 106.96 (+4.40), SUNE: 9.22 (+0.42), DPZ: 106.30 (+1.28), TWTR: 25.03 (+0.65), PLNT: 15.90 (+0.63), ZU: 17.75 (+0.18), REGN: 535.47 (+36.45)
EQUITY ALERT: The Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Biogen Inc. to Recover Investor Losses
Business Wire - Tue Aug 18, 5:35PM CDT
The Rosen Law Firm, a global investor rights firm, announces that a class action lawsuit has been filed on behalf of all purchasers of Biogen Inc. (NASDAQ:BIIB) securities from January 29, 2015 through July 23, 2015, inclusive (the "Class Period"
. The lawsuit seeks to recover investors' losses under the federal securities laws. BIIB: 298.25 (+16.51)
